Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H1299 Vaccine +/- N-803 in PD-L1 Negative NSCLC
NCT05642195Phase 2Suspended
- Sponsor
- National Cancer Institute
- Start
- Nov 2026
- Primary completion
- Dec 2033
- Countries
- 1
01
Overview
Phase 2, open-label trial of H1299 lysate vaccine and nogapendekin alfa inbakicept in non-small cell lung cancer (NSCLC) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Frequency of immunologic responses to purified CT-X and autosomal CT antigens and Safety and tolerability. Started Nov 2026; status: suspended.
02
Drugs
H1299 lysate vaccinenogapendekin alfa inbakicept
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05642195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05642195.